{"downloaded": true, "htmlmade": false, "full": {"id": "31498131", "source": "MED", "pmid": "31498131", "pmcid": "PMC6839453", "fullTextIdList": {"fullTextId": "PMC6839453"}, "doi": "10.3233/jpd-191711", "title": "Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review.", "authorString": "Boertien JM, Pereira PAB, Aho VTE, Scheperjans F.", "authorList": {"author": [{"fullName": "Boertien JM", "firstName": "Jeffrey M", "lastName": "Boertien", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Parkinson Expertise Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}}}, {"fullName": "Pereira PAB", "firstName": "Pedro A B", "lastName": "Pereira", "initials": "PAB", "authorId": {"@type": "ORCID", "#text": "0000-0002-2967-2252"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Helsinki, Finland."}, {"affiliation": "Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Helsinki, Finland."}]}}, {"fullName": "Aho VTE", "firstName": "Velma T E", "lastName": "Aho", "initials": "VTE", "authorId": {"@type": "ORCID", "#text": "0000-0003-2916-7018"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Helsinki, Finland."}, {"affiliation": "Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Helsinki, Finland."}]}}, {"fullName": "Scheperjans F", "firstName": "Filip", "lastName": "Scheperjans", "initials": "F", "authorId": {"@type": "ORCID", "#text": "0000-0001-9502-7131"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Helsinki, Finland."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-9502-7131"}, {"@type": "ORCID", "#text": "0000-0002-2967-2252"}, {"@type": "ORCID", "#text": "0000-0003-2916-7018"}]}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "s2", "volume": "9", "journalIssueId": "2877535", "dateOfPublication": "2019", "monthOfPublication": "0", "yearOfPublication": "2019", "printPublicationDate": "2019-01-01", "journal": {"title": "Journal of Parkinson's disease", "ISOAbbreviation": "J Parkinsons Dis", "medlineAbbreviation": "J Parkinsons Dis", "NLMid": "101567362", "ISSN": "1877-7171", "ESSN": "1877-718X"}}, "pubYear": "2019", "pageInfo": "S297-S312", "abstractText": "Gut microbiota have been studied in relation to the pathophysiology of Parkinson's disease (PD) due to the early gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies, various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset with atypical parkinsonism cohorts, prodromal and treatment-na\u00efve de novo PD subjects, measurements of fecal microbial concentrations and multi-omics assessments are required to provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.", "affiliation": "Department of Neurology, Parkinson Expertise Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "Systematic Review", "review-article", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Parkinson Disease", "meshQualifierList": {"meshQualifier": {"abbreviation": "MI", "qualifierName": "microbiology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "Y", "descriptorName": "Gastrointestinal Microbiome"}]}, "keywordList": {"keyword": ["Parkinson disease", "Systematic review", "case-control studies", "Gut Microbiome"]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3233/JPD-191711"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6839453"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6839453?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "23", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2020-07-27", "dateOfCreation": "2019-09-10", "firstIndexDate": "2019-09-10", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2020-07-27", "firstPublicationDate": "2019-01-01"}, "htmllinks": "https://europepmc.org/articles/PMC6839453", "abstract": "Gut microbiota have been studied in relation to the pathophysiology of Parkinson's disease (PD) due to the early gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies, various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset with atypical parkinsonism cohorts, prodromal and treatment-na\u00efve de novo PD subjects, measurements of fecal microbial concentrations and multi-omics assessments are required to provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.", "Keywords": ["Parkinson disease", "Systematic review", "case-control studies", "Gut Microbiome"], "pdflinks": "https://europepmc.org/articles/PMC6839453?pdf=render", "journaltitle": "Journal of Parkinson's disease", "authorinfo": ["Boertien JM", "Pereira PAB", "Aho VTE", "Scheperjans F"], "title": "Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review."}